STOCK TITAN

Beam Therapeutics Inc - BEAM STOCK NEWS

Welcome to our dedicated news page for Beam Therapeutics (Ticker: BEAM), a resource for investors and traders seeking the latest updates and insights on Beam Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Beam Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Beam Therapeutics's position in the market.

Rhea-AI Summary
Beam Therapeutics Inc. initiates Phase 1/2 trial of BEAM-302 in AATD, receiving clearance for clinical trial authorization in the UK. BEAM-302 aims to correct the PiZ mutation associated with severe AATD, potentially offering a promising treatment for patients with alpha-1 antitrypsin deficiency.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.4%
Tags
-
Rhea-AI Summary
Beam Therapeutics Inc. (BEAM) will participate in upcoming investor conferences to discuss its precision genetic medicines through base editing. The conferences include TD Cowen 44th Annual Health Care Conference, Leerink Partners Global Biopharma Conference, and Barclays Global Healthcare Conference. The webcasts will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.24%
Tags
conferences
-
Rhea-AI Summary
Beam Therapeutics Inc. (BEAM) reports progress in patient dosing for BEAM-101 in Severe Sickle Cell Disease and plans to release first clinical data in the second half of 2024. The company also anticipates initiating Phase 1 trials for BEAM-302 in Alpha-1 Antitrypsin Deficiency in the first half of 2024. Beam ended the fourth quarter of 2023 with $1.2 billion in cash, cash equivalents, and marketable securities, projecting financial stability until 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.89%
Tags
Rhea-AI Summary
Beam Therapeutics Inc. will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on February 8, 2024. The company is developing precision genetic medicines through base editing. The event will be live webcasted and archived for 60 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.04%
Tags
conferences
-
Rhea-AI Summary
Beam Therapeutics Inc. (Nasdaq: BEAM) reported progress in their clinical programs for sickle cell disease and alpha-1 antitrypsin deficiency. The company dosed the first patient in their BEACON Phase 1/2 clinical trial for BEAM-101 and submitted a European Clinical Trial Application for BEAM-302. They also provided updates on their anticipated upcoming milestones, including an IND application for BEAM-301 and cash runway expected to support operating plans into 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.87%
Tags
none
-
Rhea-AI Summary
Beam Therapeutics Inc. (Nasdaq: BEAM) will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024. The company is a biotechnology company developing precision genetic medicines through base editing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
conferences
Rhea-AI Summary
Beam Therapeutics Inc. (Nasdaq: BEAM) appoints Christi Shaw, a biopharmaceutical industry veteran, to its board of directors. Shaw's extensive experience includes leadership roles at Kite, Eli Lilly, and Novartis. Her appointment reflects Beam's commitment to advancing its pipeline of base editing therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.34%
Tags
management
-
Rhea-AI Summary
Beam Therapeutics Inc. (Nasdaq: BEAM) reported third quarter 2023 financial results and announced a portfolio prioritization focusing on precision genetic medicines. They acquired the opt-in rights to Verve Therapeutics' base editing cardiovascular programs for up to $600 million from Lilly. The company has initiated GMP operations at its North Carolina manufacturing facility and expects to fund its operating expenses until the second half of 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.36%
Tags
-
Rhea-AI Summary
Beam Therapeutics Inc. (Nasdaq: BEAM) CEO John Evans to Speak at 2023 Jefferies London Healthcare Conference on November 15, 2023. Live webcast available on company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.36%
Tags
conferences
Rhea-AI Summary
Beam Therapeutics Inc. has announced that Eli Lilly and Company will acquire certain rights under Beam's collaboration and license agreement with Verve Therapeutics. The deal includes Beam's opt-in rights to co-develop and co-commercialize Verve's base editing programs for cardiovascular disease. Beam will receive a $200 million upfront payment and $50 million equity investment, with the potential for up to $600 million in total deal consideration. This partnership provides capital for Beam's portfolio of clinical and research-stage programs and expands Verve's reach with Lilly's expertise in the cardiovascular space.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.62%
Tags
Beam Therapeutics Inc

Nasdaq:BEAM

BEAM Rankings

BEAM Stock Data

2.10B
73.33M
1.84%
89.58%
16.47%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Cambridge

About BEAM

beam therapeutics is developing precision genetic medicines for serious diseases. co-founded by scientific pioneers known for advancing crispr gene editing, we’re the first company to pursue development of new therapies using crispr base editing technology. we aim to use these technologies to generate a broad pipeline of precision genetic medicines that repair disease-causing point mutations, write in protective genetic variations, or modulate the expression or function of disease-causing genes. who we are beam is creating precision genetic medicines through base editing why we do it our dream is to provide life-long cures for patients suffering from serious diseases who we are and how we work together the beam team:  a community of fearless innovators  rigorous and honest in our research  listening with open minds  committed to each other